Effect of Carbohydrate Feeding on the Bone Metabolic Response to Running

Authors: Craig Sale¹, Ian Varley¹, Thomas W. Jones², Ruth M. James¹, Jonathan C.Y. Tang³, William D. Fraser³,⁴, Julie P. Greeves⁵.

Affiliations: ¹Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement Research Centre, School of Science and Technology, Nottingham Trent University, UK. ²Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK. ³Norwich Medical School, University of East Anglia, UK. ⁴Norfolk and Norwich University Hospital, Norwich, UK. ⁵Department of Occupational Medicine, HQ Army Recruiting and Training Division, Upavon, UK.

Conflicts of interest and source of funding: This work was funded by the UK Ministry of Defence (Army). The authors have no conflicts of interest.

Running head: Carbohydrate and Bone Metabolism With Exercise.

Correspondence: Dr Craig Sale, Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement Research Centre, School of Science and Technology, Nottingham Trent University, NG11 8NS, UK. E-mail: craig.sale@ntu.ac.uk.
ABSTRACT

PURPOSE: Bone resorption is increased following running, with no change in bone formation. Feeding during exercise might attenuate this increase, preventing associated problems for bone. This study investigated the immediate and short-term bone metabolic responses to carbohydrate (CHO) feeding during treadmill running. METHODS: Ten men completed two 7 d trials, once being fed CHO (8% glucose immediately before, every 20 min during and immediately after exercise at a rate of 0.7 gCHO·kg⁻¹BM·h⁻¹) and once placebo (PBO). On day 4 of each trial, participants completed a 120 min treadmill run at 70% VO₂max. Blood was taken at baseline (BASE) immediately after exercise (EE), after 60 (R1) and 120 (R2) min of recovery and on 3 follow-up days (FU1-FU3). Markers of bone resorption (β-CTX) and formation (P1NP) were measured, along with OC, PTH, ACa, PO₄, GLP-2, IL-6, insulin, cortisol, leptin and OPG. Area under the curve was calculated in terms of the immediate (BASE, EE, R1 and R2) and short-term (BASE, FU1, FU2 and FU3) responses to exercise. RESULTS: β-CTX, P1NP and IL-6 responses to exercise were significantly lower in the immediate post-exercise period with CHO feeding when compared with PBO (β-CTX: P=0.028; P1NP: P=0.021; IL-6: P=0.036), although there was no difference in the short-term response (β-CTX: P=0.856; P1NP: P=0.721; IL-6: P=0.327). No other variable was significantly affected by CHO feeding during exercise. CONCLUSION: CHO feeding during exercise attenuated the β-CTX and P1NP responses in the hours but not days following exercise, indicating an acute effect of CHO feeding on bone turnover.
**Key words:** carbohydrate, feeding, bone metabolism, running, exercise.

**INTRODUCTION**

Feeding influences the circadian rhythm of bone metabolism at rest (17). Markers of bone resorption decrease following mixed meal feeding (3) and ingestion of individual macronutrients at rest (1,7). Reductions in bone resorption occur following oral but not parenteral administration of glucose, suggesting that enteric hormones might play a part in mediating the effects of glucose on bone metabolism (1). This is supported by studies showing that Octreotide administration, an inhibitor of enteric hormone secretion, abolishes the reduction in bone resorption following glucose ingestion (4). These findings suggest a potential means to modulate bone turnover by nutritional strategies or through manipulation of dietary composition (21).

Exhaustive weight-bearing exercise increases bone resorption by 40-45% for up to four consecutive days without a concomitant increase in bone formation, potentially resulting in a short-term net loss of bone (19). Attenuating bone resorption is a potential countermeasure to the bone uncoupling shown to occur with exercise that might predispose athletes and military recruits to stress fractures and other associated injuries (22). Feeding practices, before, during and after exercise, influence the interaction between exercise and bone turnover, making them potentially important for offsetting bone loss. Scott et al. (18) showed that feeding a mixed meal prior to exercise reduced β-CTX concentrations before a 60 min treadmill run, although the subsequent increase in β-CTX during exercise was similar
in fed and fasted groups. This indicated a novel interaction between feeding, exercise and bone metabolism that requires further study, particularly in relation to feeding practices during and after exercise.

Carbohydrate, fat and protein all decrease β-CTX (3,4); CHO ingestion during exercise is an established nutritional practice for athletes, proven to enhance physical performance and exercise capacity by providing additional fuel to the muscle (11). A recent study (5) suggests that CHO is a candidate nutrient for modulating bone resorption during an exercise programme (8 d intensive training), although factors that may have mediated these responses were not examined.

The aim of this study was to investigate the responses of bone metabolism to CHO feeding during exercise in the hours (immediate) and days (short-term) following a single bout of strenuous treadmill running. We also measured markers associated with feeding, exercise and bone to explore possible mediating and mechanistic factors.
METHOD

Participants

Ten healthy, physically active men (mean ± SD, age 24 ± 3 years, height 1.75 ± 0.08 m, body mass 72.9 ± 7.5 kg, body fat percentage 14.3 ± 2.4%, VO$_{2\text{max}}$ 53.0 ± 6.4 ml·kg$^{-1}$·min$^{-1}$) provided informed consent and completed medical history questionnaires. The institutional research ethics committee approved the study in accordance with the declaration of Helsinki.

Participants were included if they were non-smokers, had not suffered a bone fracture or injury of any type in the previous 12 months, were free from musculoskeletal injury, were not taking any medication and were not suffering from any condition known to affect bone metabolism. Eligibility of each participant was confirmed verbally and with a medical screening questionnaire.

Experimental Design

All participants completed two randomised, repeated measures, counterbalanced 7 d experimental trials, involving either placebo (PBO) or carbohydrate (CHO) ingestion during 120 min of treadmill running at 70% of maximal oxygen consumption (VO$_{2\text{max}}$). Trials were separated by 14 d to allow participants to recover from blood sampling and dietary control and to allow bone marker concentrations to return to baseline values. Participants were required to refrain from exercise, caffeine and alcohol consumption for 48 h prior to trials. Participants recorded dietary intake during
the first trial and repeated the same dietary pattern during the second trial to control for the influence of feeding on bone metabolism (21).

Experimental Procedures

Preliminary Measurements

Height and body mass were recorded before body fat analysis was conducted by bioelectrical impedance (Bodystat 1500, Bodystat LTD, Isle of Man). Preliminary testing also involved the assessment of the cardio-respiratory responses to running. Participants first performed a sub-maximal test to establish the relationship between running speed and oxygen consumption during level running, which was completed at a 0% gradient from a gentle starting speed. The speed of the treadmill was increased by 1 km·h⁻¹ at 3-min intervals for at least 15 min (5 stages). Expired air (~1 min, inspiration to inspiration) was collected into Douglas Bags during the last minute of each stage to determine oxygen consumption. Oxygen consumption at each stage of the sub-maximal test was plotted against the running speed at that stage so that the relationship between running speed and oxygen consumption could be determined.

The maximum oxygen uptake test was then performed following a 15 min recovery period, consisting of a continuous incremental uphill running test at constant speed until volitional exhaustion. Running speed for this test was determined from the results of the sub-maximal test. The gradient of the
treadmill was increased by 1% at the end of each minute from a starting gradient of 0%. Once maximum oxygen uptake was determined, the oxygen consumption representing 70% \( \text{VO}_{2\text{max}} \) was calculated. Using the data from the sub-maximal running test, the running speed that elicited 70% of \( \text{VO}_{2\text{max}} \) at a 0% gradient was determined.

**Trial Days 1 – 3**

Participants adhered to their normal diet and refrained from exercise or strenuous physical exertion. Participants recorded their dietary intake and were asked about lifestyle activity (e.g., feelings of fatigue, sleep patterns), with diet and sleep patterns being replicated between trials.

**Trial Day 4**

Participants attended the laboratory (0800 h) after an overnight fast (since 2000 h the previous evening) and remained fasted until the final blood sample was drawn. On arrival, nude body mass was determined and participants then rested in a semi-recumbent position and were fitted with a heart rate monitor (Polar FS1, Polar Electro, Finland). At 0830 h, a resting blood sample (BASE) was withdrawn from a prominent forearm vein. Participants then completed 120 min of running on a treadmill (h/p/cosmos, Pulsar 4.0) at 70% \( \text{VO}_{2\text{max}} \). Further blood samples were withdrawn immediately after exercise (EE) (1100 h) and after 60 (R1) (1200 h) and 120 (R2) (1300 h) min of
recovery. Heart rate and ratings of perceived exertion (6-20 scale; Borg 1970) were recorded pre-exercise and at 10 min intervals throughout exercise for participant monitoring purposes.

During the CHO trial, participants ingested an 8% glucose solution immediately before, every 20 min during and immediately after exercise at a rate of 0.7 gCHO·kg⁻¹BM·h⁻¹. The total amount of glucose ingested was 102.1±10.6 g in a total solution volume of 1276±132 mL. These totals were divided equally over 7 mean ingestions of 14.6±1.5 g of glucose in 182±19 mL of solution. During PBO, participants ingested equal volumes of a taste-matched flavoured water drink containing no CHO.

Upon completion of exercise, nude body mass was determined and participants consumed water equal to 150% of the body mass lost over the subsequent 120 min. Participants were instructed not to perform any other further exercise.

**Trial Days 5 – 7**

Participants attended the laboratory (0800 h) following an overnight fast (from 2000 h the previous evening) and rested for 30 min, following which a blood sample was withdrawn (0830 h) from a prominent forearm vein. During this time, participants continued to record their diet and maintained dietary control and refrained from all exercise.
Storage and Analyses of Venous Blood

15 mL of venous blood was dispensed into three 5 mL tubes lined with ethylenediaminetetraacetic acid (EDTA) and centrifuged immediately for 10 min at 2000xg at 4°C. Following centrifugation, plasma was dispensed into Eppendorf tubes and stored at -80°C for subsequent analyses of C-terminal telopeptide region of collagen type 1 (β-CTX), N-terminal propeptides of procollagen type 1 (P1NP), osteoprotogerin (OPG), osteocalcin (OC), parathyroid hormone (PTH), leptin, glucagon like peptide-2 (GLP-2) and interleukin-6 (IL-6). Prior to storage, measurements of plasma glucose and lactate were performed (Yellow Springs Instruments, 2300 STAT Plus, YSI Ltd, UK).

β-CTX, P1NP, OC and PTH were measured using electrochemiluminescent immunoassays (ECLIA) on a Modular Analytics E170 analyser (Roche Diagnostics, Burgess Hill, UK). Inter-assay coefficient of variation for β-CTX (CV) was <3% between 0.2 and 1.5 ug·L⁻¹, with sensitivity of 0.01 ug·L⁻¹. P1NP inter-assay CV was <3% between 20-600 ug·L⁻¹ and sensitivity of 8 ug·L⁻¹. OC inter-assay CV was <5% between 2-200 ug·L⁻¹ and sensitivity of 0.6 ug·L⁻¹. PTH inter-assay CV of <4% between 1-30 pmol/L and sensitivity of 0.8 pmol/L. OPG was measured using an enzyme linked immunosorbent assay (ELISA) supplied by Immuno Diagnostic Systems (IDS) (Boldon UK), with an inter-assay CV of <8% across the range 1-30 pmol·L⁻¹ and sensitivity of 0.14 pmol·L⁻¹. Leptin was measured using ELISA supplied by IDS, having an inter-assay CV of <8% across the range 3-50 ug·L⁻¹ and sensitivity of 1 ug·L⁻¹. GLP-2 was measured using ELISA (Yanaihara Institute Inc,
Japan), with an inter-assay CV of 1.1-11.1% across the range 3.1-33.4 ng·mL\(^{-1}\) and detection limit of 0.5 ng·mL\(^{-1}\). IL-6 was measured using ELISA (Quantikine HS, R&D Systems Ltd, UK), with an inter-assay CV of <10% across the range 0.15-10 pg·mL\(^{-1}\) and detection limit of 0.039 pg·mL\(^{-1}\).

The remaining 5 mL of venous blood was dispensed into a serum tube and allowed to clot at room temperature for 60 min before being centrifuged for 10 min at 2000xg at 4°C. Resultant serum was dispensed into Eppendorf tubes and stored at -80°C for the subsequent analysis of cortisol, insulin, calcium, albumin and phosphate (PO\(_4\)).

Cortisol was measured using an ECLIA on the Roche Modular E170, with an inter-assay CV of <6% between 16 and 1750 nmol·L\(^{-1}\) and sensitivity of 8 nmol·L\(^{-1}\). Insulin was measured using ECLIA on a Cobas e601 (Roche Diagnostics, Burgess Hill, UK), having an inter-assay CV of <6.1% across the range 44-505 pmol·L\(^{-1}\) and sensitivity of 1.8 pmol·L\(^{-1}\). Calcium, albumin and phosphate were measured using standard commercial assays supplied by Roche Diagnostics performed on the Roche Modular E170. The range of measurement in serum is 0.05-5.00 mmol·L\(^{-1}\) for calcium, 10-70 g·L\(^{-1}\) for albumin and 0.10-6.46 mmol·L\(^{-1}\) for phosphate.

*Statistical Analysis*
Data are presented as mean ±1SD and statistical significance was accepted at P ≤ 0.05. Data were analysed using SPSS V20. Effects of exercise were assessed on the PBO trial data using a one-way ANOVA for normally distributed data, and a Friedman’s ANOVA for non-normally distributed data. Within exercise variables were analysed using a repeated measures ANOVA. The area under the curve (AUC) with respect to BASE was calculated for all biochemistry markers from the percentage change data (23) for the immediate (BASE, EE, R1 and R2) and short-term (BASE, FU1, FU2 and FU3) responses to exercise. The two conditions were then compared using a paired samples t-test for normally distributed data, or a Wilcoxon’s test for non-normally distributed data.
RESULTS

BASE biochemistry

Table 1 shows the mean±1SD concentrations for all variables. There were no differences between trials for any of the measures taken at BASE (P values from 0.143-0.990, data not shown).

Exercise variables

There were no significant differences between PBO and CHO for RPE (P=0.473) or HR (P=0.869), but, as expected, both increased over the duration of the exercise bout (P<0.001). There was also no interaction between condition and time for either RPE (P=0.847) or HR (P=0.170). Blood glucose concentrations (Figure 1) remained relatively unchanged during PBO (BASE: 4.74±0.32 mmol·L\(^{-1}\); EE: 4.82±0.84 mmol·L\(^{-1}\); R1: 4.38±0.36 mmol·L\(^{-1}\); R2: 4.35±0.35 mmol·L\(^{-1}\)), but were significantly elevated with CHO feeding (P=0.002) at EE (6.32±0.62 mmol·L\(^{-1}\)) compared with BASE (4.87±0.16 mmol·L\(^{-1}\)). Blood glucose concentrations were significantly (P<0.001) higher in the CHO than in the PBO trial at EE. Blood lactate concentrations (Figure 1) increased significantly from BASE to EE (P=0.002) before returning back towards BASE during recovery.

Markers of bone metabolism

\(\beta\)-CTX increased by between 6 and 14% from BASE to the follow-up days in PBO (BASE: 0.54±0.14 ng·mL\(^{-1}\); FU1: 0.56±0.14 ng·mL\(^{-1}\); FU2: 0.58±0.19 ng·mL\(^{-1}\); FU3: 0.61±0.16 ng·mL\(^{-1}\). Table 1).
AUC analysis showed that the β-CTX response to exercise was significantly lower in the immediate post-exercise period with CHO than with PBO (P=0.028; Figure 2A), although there was no difference in short-term response over the follow-up days (P=0.856; Figure 2B).

On the follow up days, P1NP was 5 to 14% (FU1: 67.9±33.2 ng·mL⁻¹; FU2: 66.2±31.7 ng·mL⁻¹; 68.4±28.0 ng·mL⁻¹) higher than at BASE (63.1±30.5 ng·mL⁻¹) in the PBO trial (Table 1). AUC analysis showed significantly lower P1NP concentrations in the CHO trial compared to the PBO trial in the hours following exercise (P=0.021; Figure 2A), but there was no differences between trials over the follow-up days (P=0.721; Figure 2B).

OC concentrations were not affected by exercise in the PBO trial (Table 1) or by CHO ingestion during exercise either in the immediate (P=0.343; Figure 2A) or short-term (P=0.786; Figure 2B) recovery periods.

*Modulators of calcium metabolism*

PTH increased (P<0.001) by 87% at EE (6.6±2.0 pmol·L⁻¹) compared with BASE (3.7±1.2 pmol·L⁻¹) in PBO. Thereafter, concentrations returned towards BASE levels and were slightly lower than BASE at R1 (3.6±1.2 pmol·L⁻¹) and R2 (3.3±1.3 pmol·L⁻¹). PO₄ was increased by 21% at EE (1.4±0.1 mmol·L⁻¹) due to the exercise bout (P<0.001), and then returned to BASE values (1.1±0.1
mmol·L\(^{-1}\)) by R1 (1.1±0.2 mmol·L\(^{-1}\)). No exercise effect was shown for ACa in PBO (P=0.871). There were no immediate or short-term effects of CHO feeding on calcium metabolism markers (Table 2).

*Other modulators of bone metabolism*

Significant effects of exercise (PBO trial) were shown for insulin (P<0.001), IL-6 (P<0.001) and leptin (P<0.01), but there were no significant effects of exercise on cortisol, OPG, or GLP-2. CHO feeding significantly attenuated the elevation in IL-6 concentrations (223%) seen immediately following exercise in the PBO trial (Table 2; P=0.036), although these differences did not persist over the follow-up days (P=0.327). There were no other immediate or short-term effects of CHO feeding on any of the remaining modulators of bone metabolism measured (Table 2).
DISCUSSION

Our main findings were that: 1) CHO feeding during exercise attenuated the β-CTX and P1NP responses in the hours but not days following exercise; 2) IL-6 responded in a similar manner to bone turnover following CHO feeding during exercise.

The reduction in bone resorption with CHO feeding during strenuous exercise suggests a potential strategy for athletes and those performing arduous occupational training (e.g., the military recruit) to minimise increased bone resorption resulting from such exercise (19). From the results of the present investigation, it should be noted, however, that the magnitude of the effect of CHO feeding on β-CTX concentrations was relatively small, which in itself might not be that clinically significant. If these effects were repeatable over subsequent strenuous exercise bouts (as would be the case during athletic or military training programmes), however, then there would likely be a physiological or clinical benefit. Future studies should determine the effect of repeated feeding during exercise across a training programme on bone turnover. In the present study, it should also be noted that CHO feeding attenuated the exercise induced increase in P1NP, indicating that the dynamic balance between bone resorption and formation was somewhat maintained. The bone turnover marker responses to CHO ingestion during exercise in the present study are similar to the responses observed by others at rest (3) where a reduction in β-CTX (18%) and P1NP (4%) in response to breakfast feeding when compared with fasting was observed. Whilst this is consistent with the present findings incorporating
an exercise intervention, it does not concur with our previous study (18), which showed that resting concentrations of \(\beta\)-CTX, but not P1NP or OC, were reduced following a pre-exercise mixed meal compared with fasting.

One possible explanation for the immediate effects of CHO feeding on the bone resorption response to exercise is the concomitant reduction in the IL-6 response, with a strong correlation \((r = 0.74; P<0.05)\) existing between the immediate responses of IL-6 and \(\beta\)-CTX in the CHO trial. The ingestion of CHO before and during endurance exercise attenuates the rise in circulating IL-6 associated with exercise \((13,14)\). Starkie et al. \((20)\) showed that a total ingestion of 64±3 g of CHO before and during 60 min of running and cycling attenuated the rise in plasma IL-6 associated with both modes of exercise. Increases in circulating cytokines \((15,16)\) have been shown in response to heavy or unaccustomed exercise and might have a regulatory function in bone metabolism \((12)\), potentially providing a mechanism that underpins the observed short-term effect of CHO ingestion during exercise on bone metabolism. Evidence from in vitro and animal models suggests that IL-6 is an activator of osteoclastogenesis and bone resorption \((Kotake et al., 1996)\). It can stimulate osteoclast differentiation but can also, in the presence of soluble IL-6 receptors \((sIL-6R)\), stimulate osteoclast activity \((Kotake et al., 1996)\). Palmqvist et al. \((2002)\) has shown that IL-6, when combined with its soluble receptor, stimulate bone resorption, as well as mRNA and protein expression of receptor activator of nuclear factor \(\kappa\)B ligand \((RANKL)\) and OPG in murine calvarial bone. \(sIL-6R\) can bind
its ligand and induce cellular responses through association with the glycoprotein 130 receptor subunit (gp130), thus acting as an IL-6 agonist. IL-6 stimulates gp130 on stromal or osteoblastic cells; subsequently resulting in downstream signal transducer and activator transcription 3 mediated expression of RANKL and the stimulation of osteoclast formation. In addition, others (Rifas and Avioli, 1999) have suggested the presence of a T-cell cytokine that can stimulate IL-6 in human osteoblastic cells. Whilst this indicates a potential mechanism for the current findings, it should be noted that there was no effect of CHO feeding on circulating OPG concentrations and we cannot confirm the circulating sIL-6R or RANKL concentrations in the present study. Previous studies have suggested an effect of exercise on sIL-6R concentrations (for review see Peake et al., 2015) but there is no study, to our knowledge, that has reported the effects of CHO feeding. The measurement of circulating RANKL concentrations was not possible in the present study due to the lack of a suitable assay. Lastly, with the measurement of circulating concentrations it is not possible to be certain of the biological actions occurring in particular tissues.

There was a significantly attenuated P1NP response in the hours after exercise in the CHO trial when compared with the placebo trial, suggesting that CHO feeding during prolonged exercise affects bone formation in addition to bone resorption. There was no concomitant effect on circulating OC concentrations, which is inconsistent with the P1NP and IL-6 responses to CHO ingestion during exercise in the present study, since some have suggested that it is a marker of overall coupled bone
turnover (9) and is capable of suppressing IL-6 release (8) and has importance in the relationship between bone remodelling and energy metabolism (6). Clearly, the present data do not add support to these previous findings.

The response of P1NP in concert with the effect shown on β-CTX would suggest that CHO feeding during exercise reduced overall bone turnover in the hours following exercise but the balance between resorption and formation was maintained. Whilst a reduction in IL-6 release during exercise with CHO feeding is a plausible mechanism to explain the observed reduction in β-CTX concentrations, the reason for the attenuated post-exercise P1NP concentrations with CHO feeding during exercise is currently unknown, but is likely to involve cellular cross-talk between the osteoclasts and osteoblasts given their very close association.

Potential mechanisms for the suppression of bone turnover by CHO feeding during exercise relate to effects on PTH, or on the incretin and enteric hormones. Bone turnover was decreased along with PTH in a previous study employing the hypoglycaemic clamping technique (4), suggesting that short-term alterations to bone turnover are due to direct effects of hypoglycaemia (glucose concentrations were clamped at 2.5 mmol·L⁻¹ for 105 min) on bone cells or are mediated by changes in regulatory hormone concentrations triggered by hypoglycaemia (4). The present study did not show any immediate effect of CHO provision during exercise on the circulating concentrations of PTH, ACa or
PO₄, making it unlikely that the effects of CHO supplementation during exercise on bone turnover were mediated by alterations in calcium metabolism. CHO did not significantly alter the immediate or short-term responses of leptin, insulin, cortisol or GLP-2 to exercise, indicating that alterations in these hormones were also unlikely to be responsible for the effect of CHO supplementation on bone turnover shown. Despite the fact that the present study involved 120 min of running at 70% VO₂max, blood glucose concentrations remained relatively stable, even when participants were not fed CHO in the PBO trial, with blood glucose concentrations not reaching hypoglycaemic levels.

Given that the data from the PBO trial show a 5-15% increase in β-CTX during the follow up days, when compared to BASE, and others (19) also report greater and more prolonged increases in β-CTX following exhaustive exercise, it is clear that CHO feeding during exercise alone might not be sufficient to result in a more prolonged or greater suppression of the increase in bone resorption. This might be because the amount of CHO provided (102.1 ± 10.6 g) during exercise was not sufficient to prolong the effect observed during the early recovery period, possibly because the CHO was used by the muscle to support glycogen re-synthesis. Another possibility is that participants resumed their habitual diet once leaving the laboratory on D4, meaning that any extra CHO provided during exercise in the CHO trial would become less meaningful as a proportion of the total daily energy intake. As such, the clinical implications of the present study findings remain unclear; future work could explore higher CHO intakes during exercise, or the maintenance of high CHO intakes in the
days following exercise for skeletal benefits. The amount of CHO provided during exercise in the current study (~50 g·h⁻¹) is consistent with the amount and rate typically recommended for endurance exercise benefits (10), although in current practice athletes typically consume 60 to 70 g·h⁻¹ (11) and athletes performing prolonged exercise (e.g., triathletes) are advised to increase their CHO intake (from multiple CHO sources) to 80-90 g·h⁻¹ (11).

In conclusion, CHO supplementation during prolonged running reduced bone turnover in the hours following exercise. A possible mediator of the immediate bone resorption response to exercise when fed CHO during exercise was IL-6. The mechanism underlying the reduced P1NP response remains unknown. No changes in markers of calcium metabolism or the incretin and enteric hormone concentrations were observed with CHO feeding, suggesting that they are unlikely mediators of the effect of CHO on bone turnover.
ACKNOWLEDGEMENTS

We would like to thank Graham Ball (Professor of Biostatistics and Bioinformatics, John van Geest Cancer Research Centre, Nottingham Trent University) for his advice on the statistical approach.
REFERENCES

1. Bjarnason NH, Henriksen EEG, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. *Bone*. 30: 307-313, 2002.

2. Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. *Journal of Clinical Endocrinology & Metabolism*. 88: 4867-4873, 2003.

3. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. *Bone*. 30: 886-890, 2002.

4. Clowes JA, Robinson RT, Heller SR, Eastell R, Blumsohn A. Acute changes of bone turnover and PTH induced by insulin and glucose: euglycaemic and hypoglycemic hyperinsulinemic clamp studies. *Journal of Clinical Endocrinology & Metabolism*. 87: 3324-3329, 2002.

5. de Sousa MV, Pereira RM, Fukui R, Caparbo VF, da Silva ME. Carbohydrate beverages attenuate bone resorption markers in elite runners. *Metabolism*. 63: 1536-1541, 2014.

6. Ducy P. The role of osteocalcin in the endocrine cross-talk between bone remodeling and energy metabolism. *Diabetiologica*. 54: 1291-1297, 2011.

7. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsbøll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C. Role of gastrointestinal hormones in
postprandial reduction of bone resorption. *Journal of Bone and Mineral Research*. 18: 2180-2189, 2003.

8. **Hill HS, Grams J, Walton RG, Liu J, Moellering DR, Garvey WT.** Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes. *Hormone and Metabolic Research*. 46: 341-347, 2014.

9. **Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Väänänen HK.** Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. *Journal of Biological Chemistry*. 279: 18361-18369, 2004.

10. **Jeukendrup A.** Carbohydrate feeding during exercise. *European Journal of Sport Science*. 8: 77-86, 2008.

11. **Jeukendrup, A.** A step towards personalized sports nutrition: carbohydrate intake during exercise. *Sports Medicine*. 1: S25-S33, 2014.

12. **Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y.** IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. *Cytokine & Growth Factor Reviews*. 15: 49-60, 2004.

13. **Nieman DC, Davis JM, Henson DA, Gross SJ, Dumke CL, Utter AC, Vinci DM, Carson JA, Brown A, McAnulty SR, McAnulty LS, Triplett NT.** Muscle cytokine mRNA changes after 2.5 h of cycling: influence of carbohydrate. *Medicine & Science in Sports & Exercise*. 37: 1283-1290, 2005.
14. Nieman DC, Nehlsen-Cannarella SL, Fagoaga OR, Henson DA, Utter A, Davis JM, Williams F, Butterworth DE. Influence of mode and carbohydrate on the cytokine response to heavy exertion. *Medicine & Science in Sports & Exercise*. 30: 671-678, 1998.

15. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. *Journal of Physiology*. 513: 889-894, 1998.

16. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. *Journal of Physiology*. 515: 287-291, 1999.

17. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. *European Journal of Endocrinology*. 140: 332-337, 1999.

18. Scott JP, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. Effect of fasting versus feeding on the bone metabolic response to running. *Bone*. 51: 990-999, 2012.

19. Scott JPR, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. The effects of training status on the metabolic response of bone to an acute bout of exhaustive treadmill running. *Journal of Clinical Endocrinology & Metabolism*. 95: 3918–3925, 2010.

20. Starkie RL, Arkinstall MJ, Koukoulas I, Hawley JA, Febbraio MA. Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not skeletal muscle interleukin-6 mRNA, during exercise in humans. *Journal of Physiology*. 533: 585-591, 2001.
21. Walsh JS, Henriksen DB. Feeding and bone. *Archives of Biochemistry and Biophysics*. 503: 11-19, 2010.

22. Warden SJ, Burr DB, Brukner PD. Stress fractures: pathophysiology, epidemiology, and risk factors. *Current Osteoporosis Reports*. 4: 103-109, 2006.

23. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clinical Chemistry*. 39: 561–577, 1993.
TABLE LEGENDS

Table 1. Concentrations of bone turnover markers, modulators of bone metabolism and markers of calcium metabolism at baseline (BASE), immediately following exercise (EE), during 2 h of recovery following exercise (R1-R2) and during 3 follow-up days (FU1-FU3) in the CHO and PBO trials.

Table 2. Immediate and short-term data for changes in modulators of bone and calcium metabolism with or without CHO supplementation during exercise.
FIGURE LEGENDS

Figure 1. Blood glucose (⋯) and blood lactate (—) concentration on the CHO (■) and PBO (□) trials.

*denotes a significant difference in blood glucose concentration at EE to all other time points, and between CHO and PBO trials.

Figure 2. Immediate (A) and short-term (B) recovery areas under the curve for markers of bone formation and resorption on the CHO (■) and PBO (□) trials.